Please wait while the formulary information is being retrieved.
LIDOCAINE HCL (LIDOCAINE HCL/PF)
- Administration of local anesthesia
- Ventricular arrhythmias
- Local anesthesia for endotracheal intubation
- Local anesthesia for urethral pain
- Urethritis
- Mouth irritation
- Suppression of the gag reflex
- Xylocaine-mpf Injection Solution
- Xylocaine Injection Solution
- Lta Pre-attached Laryngotracheal Solution
- Lidocaine Mucous Membrane Jelly In Applicator
- Lidocaine Mucosal Jelly In Applicator
- Lidocaine Laryngotracheal Solution
- Lidocaine Injection Solution
- Lidocaine (pf) Iv Syringe
- Lidocaine (pf) Intravenous Syringe
- Lidocaine (pf) Injection Solution
- Glydo Mucosal Jelly In Applicator
10 mg/mL (1 %) injection solution
- Dosage information is not available
15 mg/mL (1.5 %) injection solution
- Dosage information is not available
20 mg/mL (2 %) injection solution
- Dosage information is not available
5 mg/mL (0.5 %) injection solution
- Dosage information is not available
10 mg/mL (1 %) injection solution
- Dosage information is not available
20 mg/mL (2 %) injection solution
- Dosage information is not available
5 mg/mL (0.5 %) injection solution
- Dosage information is not available
4 % laryngotracheal solution
- Dosage information is not available
lidocaine 2 % mucosal jelly in applicator
- Dosage information is not available
lidocaine 2 % mucosal jelly in applicator
- Dosage information is not available
lidocaine 4 % laryngotracheal solution
- Dosage information is not available
lidocaine 10 mg/mL (1 %) injection solution
- Dosage information is not available
lidocaine 20 mg/mL (2 %) injection solution
- Dosage information is not available
lidocaine 5 mg/mL (0.5 %) injection solution
- Dosage information is not available
100 mg/5 mL (2 %) intravenous syringe
- Dosage information is not available
50 mg/5 mL (1 %) intravenous syringe
- Dosage information is not available
lidocaine (PF) 100 mg/5 mL (2 %) intravenous syringe
- Dosage information is not available
lidocaine (PF) 50 mg/5 mL (1 %) intravenous syringe
- Dosage information is not available
lidocaine (PF) 10 mg/mL (1 %) injection solution
- Dosage information is not available
lidocaine (PF) 15 mg/mL (1.5 %) injection solution
- Dosage information is not available
lidocaine (PF) 20 mg/mL (2 %) injection solution
- Dosage information is not available
lidocaine (PF) 40 mg/mL (4 %) injection solution
- Dosage information is not available
lidocaine (PF) 5 mg/mL (0.5 %) injection solution
- Dosage information is not available
2 % mucosal jelly in applicator
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- Acid Reducer (cimetidine)
- Acid Relief (cimetidine)
- Anectine
- Bystolic
- cimetidine
- Corgard
- Corzide
- Dutoprol
- Heartburn Relief
- Inderal La
- Inderal Xl
- Innopran Xl
- Lopressor
- Lopressor Hct
- metoprolol su-hydrochlorothiaz
- metoprolol succinate
- metoprolol ta-hydrochlorothiaz
- metoprolol tartrate
- nadolol
- nadolol-bendroflumethiazide
- nebivolol
- propranolol
- propranolol-hydrochlorothiazid
- Quelicin
- succinylcholine chloride
- Tagamet Hb
- Toprol Xl
- Adams-stokes syndrome
- Large open wound
- Methemoglobinemia
- Severe heart block
- Systemic lidocaine toxicity
- Wolff-parkinson-white pattern
Contraindicated
- Chronic heart failure
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Heart block
- Hemolytic anemia from PK and g6PD deficiencies
- Hypokalemia
- Hypovolemia
- Hypoxia
- Incomplete AV heart block
- Myasthenia gravis
- Respiratory depression
- Sepsis
- Shock
- Sinus bradycardia
Severe
Moderate
- Atrial fibrillation
- Disease of liver
- Respiratory depression
- Seizure disorder
LIDOCAINE HCL (LIDOCAINE HCL/PF)
- Administration of local anesthesia
- Ventricular arrhythmias
- Local anesthesia for endotracheal intubation
- Local anesthesia for urethral pain
- Urethritis
- Mouth irritation
- Suppression of the gag reflex
- None
- None
More Frequent
Severe
Less Severe
- Angioedema
- Bradycardia
- Dermatitis due to topical drug
- Erythema
- Hypotension
- Pruritus of skin
- Skin rash
- Stinging of skin
- Urticaria
- Chills
- Dizziness
- Drowsy
- Headache disorder
- Injection site sequelae
- Nervousness
- Paresthesia
- Sensation of cold
- Symptoms of anxiety
- Twitching
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute confusion
- Acute respiratory insufficiency
- Anaphylaxis
- Bradycardia
- Cardiac arrest
- Cardiac arrhythmia
- Chondrolysis of articular cartilage
- CNS toxicity
- Cyanosis
- Diplopia
- Drowsy
- Dyspnea
- Eyelid edema
- Headache disorder
- Hemiparesis
- Hypertension
- Hypotension
- Methemoglobinemia
- Myocardial dysfunction
- Nausea
- Respiratory depression
- Seizure disorder
- Skin rash
- Status asthmaticus
- Tachycardia
- Tremor
- Unconsciousness
- Urticaria
- Vasodilation of blood vessels
- Ventricular arrhythmias
- Vomiting
Less Severe
- Acute confusion
- Apprehension
- Blurred vision
- Dizziness
- Dysgeusia
- Edema
- Euphoria
- Hypesthesia
- Injection site sequelae
- Miosis
- Nervousness
- Oral hypoesthesia
- Sensation of cold
- Sensation of warmth
- Symptoms of anxiety
- Tinnitus
- Tremor
- Twitching
- Visual changes
- Vomiting
Contraindicated
None
Severe Precaution
Lidocaine (Select routes)
Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
- 1 Day – 179 Days
- Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
- 180 Days – 16 Years
- Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
Lidocaine (Top)
Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
- 1 Day – 179 Days
- Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
- 180 Days – 16 Years
- Rare risk of methemoglobinemia in infants age < 6 months. Use dose based on age, body weight and physical condition.
Management or Monitoring Precaution
Lidocaine (Top)
Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
- 180 Days – 13 Years
- Rare risk of methemoglobinemia. Use dose based on age, body weight and physical condition.
Lidocaine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Lidocaine
Amount excreted reported to be low with low infant oral bioavailability
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Amount excreted reported to be low with low infant oral bioavailability |
Contraindicated
None
Precaution Exists
Select Anesthetics
General-May be more sensitive to CNS and cardiac adverse reactions. Consider dose reduction due to reduced clearance in the elderly.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Mouth irritation | |
| K13.79 | Other lesions of oral mucosa |
| Urethritis | |
| N34.1 | Nonspecific urethritis |
| N34.2 | Other urethritis |
| Ventricular arrhythmias | |
| I49.01 | Ventricular fibrillation |
| I49.02 | Ventricular flutter |
| I49.9 | Cardiac arrhythmia, unspecified |
| 0-9 | A-Z |
|---|---|
| I49.01 | Ventricular fibrillation |
| I49.02 | Ventricular flutter |
| I49.9 | Cardiac arrhythmia, unspecified |
| K13.79 | Other lesions of oral mucosa |
| N34.1 | Nonspecific urethritis |
| N34.2 | Other urethritis |
Formulary Reference Tool